Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Collegium Pharmaceutical, Inc. (Nasdaq: COLL) provides access to the company’s official regulatory submissions as a public biopharmaceutical issuer. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information on Collegium’s financial condition, risk factors, capital structure, and governance as it advances a portfolio of pain management medications and ADHD-focused neuropsychiatry products.
Investors and analysts can use this page to review periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, key products, and risk environment, and present audited or reviewed financial statements. Current reports on Form 8-K, like those cited in recent disclosures, furnish information on material events, including quarterly financial results, earnings presentations, share repurchase authorizations, and other significant corporate actions.
For those examining executive and board matters, proxy statements on Schedule 14A and related filings provide context on governance and compensation policies. Filings related to securities offerings and credit facilities can shed light on how Collegium finances its operations and business development plans, including the use of syndicated credit arrangements and other debt instruments mentioned in company press releases.
In addition, users can monitor beneficial ownership and insider activity through forms such as Form 4, which report transactions in Collegium’s common stock by directors, officers, and certain shareholders. Understanding these filings can help readers interpret how management and insiders interact with COLL shares over time.
On Stock Titan, SEC documents for Collegium are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections on product portfolios, non-GAAP metrics, and risk factors, and make it easier to navigate complex disclosures when researching COLL as an investment or analyzing its regulatory history.
Collegium Pharmaceutical is asking shareholders to elect eight directors, approve executive pay on an advisory basis, and ratify Deloitte & Touche as auditor at its fully virtual 2026 annual meeting. Shareholders of record on March 31, 2026, representing 32,406,969 shares, may vote online, by phone, mail or during the webcast.
The proxy highlights record 2025 product revenue of $780.6 million, up 23.6%, driven by Jornay PM net revenue of $148.9 million with 48% year-over-year growth and a pain portfolio generating $631.7 million, up 6%. Operating cash flow reached $329.3 million, year-end cash and marketable securities were $386.7 million, and the company closed a $980 million syndicated credit facility while repaying about $581 million of prior term debt.
Collegium returned $25 million to shareholders via repurchases, reports strong governance with seven of eight independent directors, and emphasizes ESG initiatives, employee development, and culture. The compensation program is positioned as pay-for-performance, with a prior say-on-pay vote receiving approximately 91% support.
Collegium Pharmaceutical, Inc. announced changes to its board of directors. The board approved the nomination of Michael Donovan, 60, an audit Partner at Ernst & Young LLP since 2002, to stand for election at the 2026 Annual Meeting of Shareholders.
The company also disclosed that John Fallon, M.D., a director since 2016, will not stand for re-election and will retire from the board at the Annual Meeting. His decision is described as part of ongoing board refreshment and succession planning and not due to any disagreement with the company.
Collegium Pharmaceutical executive David Dieter reported a routine share disposition tied to tax withholding. On the vesting of restricted stock units, 8,840 shares of common stock were withheld by the company at $35.72 per share to cover applicable withholding taxes. After this non-market transaction, he directly holds 68,231 shares of Collegium Pharmaceutical common stock.
Collegium Pharmaceutical Inc amendment: The Vanguard Group reports 0 shares beneficially owned of Collegium common stock following an internal realignment. The filing states that certain Vanguard subsidiaries will report ownership separately in accordance with SEC Release No. 34-39538 (January 12, 1998).
The disclosure lists 0 shares and 0% voting and dispositive power in the issuer’s common stock and is signed by Vanguard’s Head of Global Fund Administration.
COLLEGIUM PHARMACEUTICAL, INC. executive vice president and general counsel David Dieter reported an open-market sale of 13,976 shares of common stock on March 18, 2026 at a weighted average price of $34.9241 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and executed through multiple trades between $34.74 and $35.39. Following this transaction, Dieter directly holds 77,071 shares of Collegium common stock.
Collegium Pharmaceutical plans to acquire AZSTARYS, an ADHD medicine, for $650 million in cash, plus up to $135 million in potential regulatory and commercial milestone payments. The deal will give Collegium full ownership of entities holding AZSTARYS and is expected to close in the second quarter of 2026, subject to customary conditions including Hart-Scott-Rodino clearance.
The transaction is funded by about $350 million of cash on hand and a previously announced $300 million delayed draw term loan, with net debt to adjusted EBITDA projected around 2x at closing. Collegium expects AZSTARYS to generate more than $50 million of pro forma net revenue in the second half of 2026, deliver over $50 million in annual run-rate synergies within 12 months of close, and be immediately accretive to adjusted EBITDA. Patent protection for AZSTARYS is expected to extend into 2037, strengthening Collegium’s ADHD franchise alongside JORNAY PM and further diversifying revenue beyond its pain portfolio.
Fidelity Brokerage Services LLC submitted a Form 144 reporting an intended sale of 13,976 shares of Common Stock (NASDAQ) tied to restricted stock vesting on 03/17/2026.
The filing also discloses a prior sale by David Dieter of 6,224 shares on 03/09/2026 for $228,109.60. The notice lists the broker and identifies the shares as compensation-related.
Collegium Pharmaceutical EVP & General Counsel David Dieter sold 6,224 shares of common stock at $36.65 per share in an open-market transaction. After this sale, he directly holds 91,047 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was scheduled in advance rather than timed discretionarily.